Shanghai, China – Shanghai MicroPort Endovascular MedTech Co., Ltd. ("Endovastec™") was recently awarded the 2019 Shanghai Municipal Quality Management Prize ("Prize"). The winners of the Prize were announced after the procedure including formal review, dossier assessment, panel review, on-site verification, result approval and online pre-release.
The Prize is established by Shanghai Association of Quality as a leading organization. It is mainly awarded to the organizations, projects and individuals that achieved outstanding results in quality management and business performance. The selection of the winners of the Prize for 2019 was based on GB/T 19580-2012 Criteria for Performance Excellence as basic evaluation basis and framework. The Prize aimed to guide enterprises to make in-depth application of the advanced quality management rationale and method including performance excellent model to build perfect quality management system. It also targeted to enhance the enterprises’ all-employee, all-dimension and all-process quality management to elevate quality, reduce cost and increase efficiency. Ultimately, the selection work serves the building of Shanghai's "Four Brands" and "Five Centers" and promote the high-quality development of Shanghai and the enterprises in the city.
Quality serves as the cornerstone for the development of enterprise. Endovastec™ always adheres to the orientation to quality and propelling by innovation. Choosing the path of high-quality development unswervingly, the company integrates the management model of performance excellence into corporate operations, innovation capability, quality management and social responsibility, which has achieved significant quality results and economic and public proceeds. In January 2020, Endovastec™ won the Pudong New Area Quality Gold Prize in its third selection for the company's outstanding general operational and management capabilities and results. The winning of the Shanghai Municipal Quality Management Prize fully demonstrated that the total quality management of Endovastec™ has been well recognized across the industry once again. In the future, Endovastec™ will continue to use scientific and technological innovation as an engine to focus on not only the improvement in the general strength regarding quality, R&D and management, but also the ceaseless implementation of performance excellence management model to increase the company's core competiveness.